title: Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
abstract: Cullin-RING ubiquitin ligases (CRLs) are responsible for the ubiquitination of many cellular proteins, thereby targeting them for proteasomal degradation. In most cases the substrates of the CRLs have not been identified, although many of those that are known have cancer relevance. MLN4924, an investigational small molecule that is a potent and selective inhibitor of the Nedd8-activating enzyme (NAE), is currently being explored in Phase I clinical trials. Inhibition of Nedd8-activating enzyme by MLN4924 prevents the conjugation of cullin proteins with NEDD8, resulting in inactivation of the entire family of CRLs. We have performed stable isotope labeling with amino acids in cell culture analysis of A375 melanoma cells treated with MLN4924 to identify new CRL substrates, confidently identifying and quantitating 5122-6012 proteins per time point. Proteins such as MLX, EID1, KLF5, ORC6L, MAGEA6, MORF4L2, MRFAP1, MORF4L1, and TAX1BP1 are rapidly stabilized by MLN4924, suggesting that they are novel CRL substrates. Proteins up-regulated at later times were also identified and siRNA against their corresponding genes were used to evaluate their influence on MLN4924-induced cell death. Thirty-eight proteins were identified as being particularly important for the cytotoxicity of MLN4924. Strikingly, these proteins had roles in cell cycle, DNA damage repair, and ubiquitin transfer. Therefore, the combination of RNAi with stable isotope labeling with amino acids in cell culture provides a paradigm for understanding the mechanism of action of novel agents affecting the ubiquitin proteasome system and a path to identifying mechanistic biomarkers.
authors.affiliation: Discovery, Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA.
authors.forename: Hua
authors.initials: H
authors.lastname: Liao
authors.forename: Xiaozhen J
authors.initials: XJ
authors.lastname: Liu
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Blank
authors.forename: David C
authors.initials: DC
authors.lastname: Bouck
authors.forename: Hugues
authors.initials: H
authors.lastname: Bernard
authors.forename: Khristofer
authors.initials: K
authors.lastname: Garcia
authors.forename: Eric S
authors.initials: ES
authors.lastname: Lightcap
mesh_terms: D045744:Cell Line, Tumor; D003517:Cyclopentanes / Q000494:pharmacology*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D055785:Gene Knockdown Techniques; D006801:Humans; D007700:Kinetics; D010641:Phenotype; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D055550:Protein Stability; D059748:Proteolysis; D020543:Proteome / Q000235:genetics / Q000378:metabolism*; D040901:Proteomics; D011743:Pyrimidines / Q000494:pharmacology*; D034622:RNA Interference; D044764:Ubiquitin-Activating Enzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D054875:Ubiquitination
chemical_list: D003517:Cyclopentanes; D020543:Proteome; D011743:Pyrimidines; D046988:Proteasome Endopeptidase Complex; D044764:Ubiquitin-Activating Enzymes; C539933:pevonedistat